Annual CFO
-$214.23 M
-$26.03 M-13.83%
31 March 2024
Summary:
Immunovant annual cash flow from operations is currently -$214.23 million, with the most recent change of -$26.03 million (-13.83%) on 31 March 2024. During the last 3 years, it has fallen by -$130.90 million (-157.09%). IMVT annual CFO is now -301.50% below its all-time high of -$53.36 million, reached on 31 March 2020.IMVT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$88.65 M
-$12.45 M-16.34%
30 September 2024
Summary:
Immunovant quarterly cash flow from operations is currently -$88.65 million, with the most recent change of -$12.45 million (-16.34%) on 30 September 2024. Over the past year, it has dropped by -$28.59 million (-47.60%). IMVT quarterly CFO is now -22161650.00% below its all-time high of -$400.00, reached on 31 March 2019.IMVT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$271.64 M
-$28.59 M-11.76%
30 September 2024
Summary:
Immunovant TTM cash flow from operations is currently -$271.64 million, with the most recent change of -$28.59 million (-11.76%) on 30 September 2024. Over the past year, it has dropped by -$62.02 million (-29.59%). IMVT TTM CFO is now -67910650.00% below its all-time high of -$400.00, reached on 31 March 2019.IMVT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMVT Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -13.8% | -47.6% | -29.6% |
| 3 y3 years | -157.1% | -342.2% | -213.8% |
| 5 y5 years | - | -10000.0% | -10000.0% |
IMVT Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -157.1% | at low | -342.2% | at low | -213.8% | at low |
| 5 y | 5 years | -301.5% | at low | <-9999.0% | at low | <-9999.0% | at low |
| alltime | all time | -301.5% | at low | <-9999.0% | at low | <-9999.0% | at low |
Immunovant Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$88.65 M(+16.3%) | -$271.64 M(+11.8%) |
| June 2024 | - | -$76.20 M(+27.6%) | -$243.06 M(+13.5%) |
| Mar 2024 | -$214.23 M(+13.8%) | -$59.70 M(+26.8%) | -$214.23 M(+1.9%) |
| Dec 2023 | - | -$47.10 M(-21.6%) | -$210.32 M(+0.3%) |
| Sept 2023 | - | -$60.06 M(+26.8%) | -$209.62 M(+23.5%) |
| June 2023 | - | -$47.37 M(-15.1%) | -$169.74 M(-9.8%) |
| Mar 2023 | -$188.19 M(+77.4%) | -$55.79 M(+20.3%) | -$188.19 M(+13.8%) |
| Dec 2022 | - | -$46.40 M(+129.8%) | -$165.36 M(+9.6%) |
| Sept 2022 | - | -$20.19 M(-69.3%) | -$150.86 M(+0.1%) |
| June 2022 | - | -$65.82 M(+99.7%) | -$150.72 M(+42.0%) |
| Mar 2022 | -$106.11 M | -$32.96 M(+3.3%) | -$106.11 M(+10.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | -$31.89 M(+59.1%) | -$95.65 M(+10.5%) |
| Sept 2021 | - | -$20.05 M(-5.5%) | -$86.57 M(-4.6%) |
| June 2021 | - | -$21.21 M(-5.7%) | -$90.74 M(+8.9%) |
| Mar 2021 | -$83.33 M(+56.2%) | -$22.50 M(-1.4%) | -$83.33 M(+37.0%) |
| Dec 2020 | - | -$22.82 M(-5.8%) | -$60.83 M(+60.0%) |
| Sept 2020 | - | -$24.22 M(+75.5%) | -$38.02 M(+169.6%) |
| June 2020 | - | -$13.80 M(+4476.5%) | -$14.10 M(+2549.3%) |
| Mar 2020 | -$53.36 M | - | - |
| Sept 2019 | - | -$301.50 K(+30.9%) | -$532.20 K(+130.7%) |
| June 2019 | - | -$230.30 K(>+9900.0%) | -$230.70 K(>+9900.0%) |
| Mar 2019 | - | -$400.00 | -$400.00 |
FAQ
- What is Immunovant annual cash flow from operations?
- What is the all time high annual CFO for Immunovant?
- What is Immunovant annual CFO year-on-year change?
- What is Immunovant quarterly cash flow from operations?
- What is the all time high quarterly CFO for Immunovant?
- What is Immunovant quarterly CFO year-on-year change?
- What is Immunovant TTM cash flow from operations?
- What is the all time high TTM CFO for Immunovant?
- What is Immunovant TTM CFO year-on-year change?
What is Immunovant annual cash flow from operations?
The current annual CFO of IMVT is -$214.23 M
What is the all time high annual CFO for Immunovant?
Immunovant all-time high annual cash flow from operations is -$53.36 M
What is Immunovant annual CFO year-on-year change?
Over the past year, IMVT annual cash flow from operations has changed by -$26.03 M (-13.83%)
What is Immunovant quarterly cash flow from operations?
The current quarterly CFO of IMVT is -$88.65 M
What is the all time high quarterly CFO for Immunovant?
Immunovant all-time high quarterly cash flow from operations is -$400.00
What is Immunovant quarterly CFO year-on-year change?
Over the past year, IMVT quarterly cash flow from operations has changed by -$28.59 M (-47.60%)
What is Immunovant TTM cash flow from operations?
The current TTM CFO of IMVT is -$271.64 M
What is the all time high TTM CFO for Immunovant?
Immunovant all-time high TTM cash flow from operations is -$400.00
What is Immunovant TTM CFO year-on-year change?
Over the past year, IMVT TTM cash flow from operations has changed by -$62.02 M (-29.59%)